Key products generate strong Q2 result for Lundbeck
Lundbeck reports significant growth on both the top and bottom lines for the second quarter of 2022. (Updated)
by christian bundgaard, translated by catherine brett
Sales of key products have been driving growth at Lundbeck, leading the pharmaceutical firm to upgrade its financial guidance last week.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck raises 2022 guidance
For subscribers
Lundbeck's head of R&D to join board of e-health firm Brain+
For subscribers
